Aurinia to Host Conference Call & Webcast to Review Results from the AURION Study
Conference Call and Webcast with Slides, Tuesday February 16th at 4.30pm Eastern Time
VICTORIA, British Columbia-- Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) will host a conference call and live webcast to discuss detailed results from its open label, single arm exploratory AURION (Aurinia early Urinary protein Reduction Predicts Response) study on Tuesday, February 16 at 4:30pm Eastern Standard Time. Participating in the call will be Stephen Zaruby, CEO, Dr. Neil Solomons, Chief Medical Officer, and Michael Martin, Chief Operating Officer.
Tuesday, February 16, 2016 @ 4:30pm
Conference ID: 3145908
Webcast with slides: http://public.viavid.com/index.php?id=118297
Replays, through March 1, 2016
Conference ID: 3145908
Aurinia is a clinical stage pharmaceutical company focused on the global nephrology market. The fully-enrolled 265 patient Phase 2b AURA-LV clinical trial is evaluating the efficacy of its lead drug, voclosporin, as a treatment for active LN. LN is an inflammation of the kidneys, that if inadequately treated can lead to end-stage renal disease, making LN a serious and potentially life-threatening condition.
Voclosporin is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with extensive clinical data in over 2,000 patients in other indications. Voclosporin is made by a modification of a single amino acid of the cyclosporine molecule (a CNI approved for use in transplant patients since 1983). This modification results in a more predictable pharmacokinetic and pharmacodynamic relationship, an increase in potency vs. cyclosporine, an altered metabolic profile, and potential for flat dosing.
The AURION study or “Aurinia Early Urinary Protein Reduction Predicts Response Study” is an open label, exploratory study being conducted in multiple sites in Malaysia to assess the short term predictors of response using voclosporin (23.7mg) in combination with mycophenolate mofetil and oral corticosteroids in patients with active lupus nephritis. This study will examine biomarkers of disease activity at 8 weeks and their ability to predict response at 24 and 48 weeks.
We seek Safe Harbor.
For More Information:
Aurinia Pharmaceuticals Inc.
Mr. Michael Martin, 250-708-4272
Chief Operating Officer
Renmark Financial Communications Inc.
Barry Mire, 416-644-2020
Laura Welsh, 514-939-3989
Source: Aurinia Pharmaceuticals Inc.
Released February 11, 2016